



Driving Biopharmaceutical Advancements of Plant-derived Cannabinoid-based Products

Avicanna is a commercial stage, diversified and vertically-integrated Canadian biopharmaceutical company focused on the research, development and commercialization of plant-derived cannabinoid-based products for global consumer, medical cannabis, and pharmaceutical market segments.

Advanced Product Lines

- **Pura H&W™**: an innovative, clinically tested line of CBD consumer derma-cosmetic products*
- **RHO Phyto™**: an advanced line of medical cannabis products in various deliveries and ratios of CBD and THC
- **Pharmaceuticals drugs**: Various indication specific cannabinoid based drugs in clinical development and registration phase

An Established Leader in Cannabinoid Research and Development

R&D headquarters at JLABS @ Toronto, Johnson & Johnson Innovation Centre in the MaRS Discovery District. World-class research and clinical collaborations with leading Canadian academic and medical institutions. In addition to a burgeoning pharmaceutical pipeline, Avicanna's team of experts have developed and commercialized several industry leading product lines.

World-Class Vertical Integration

Cultivation, Extraction, Purification, Production and Manufacturing




Two majority-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located in Santa Marta, Colombia. These sustainable, economical, and industrial scale subsidiaries allow Avicanna to cultivate, process, and commercialize a range of cannabis and hemp cultivars dominant in CBD, CBG, THC for use as active pharmaceutical ingredients.

Q3-2020 launch nation-wide in Canada in partnership with:



RHO Phyto™: Medical cannabis - CBD and CBD/THC

- Complete, consistent, and scientifically advanced medical cannabis formulary
- Now commercial in Canada in partnership with Medical Cannabis by Shoppers and expanding into retail sales in Q1-2021
- Now commercial in Colombia under a magisterial prescription model
- Advanced formulations with stability and pre-clinical data demonstrating enhanced bioavailability



*Expected to be marketed as Pura Earth in Canada. Pura Earth products in Colombia are being rebranded to Pura H&W

Fast Facts – January 4, 2020

Ticker (Exchange)	AVCN (TSX) AVCNF (OTCQX) ONN (Frankfurt)
Stock Price (CAD)	\$1.20
Market Cap	\$42M
Outstanding Shares	35.9M
52-Week Range	\$0.63 - \$3.00

All figures as of close of trading January 4th 2020


Investment Highlights

- Four consecutive quarters of double digit + increase in revenue and cost reductions
- Commercial stage and diversified revenue streams, across global markets including Canada, US, UK and LATAM
- Agreement with Medical Cannabis by Shoppers, for the distribution of RHO Phyto products across Canada
- Proprietary R&D, preclinical and clinical platforms including 3 years of IP development, team of 10+ scientists and world-class clinical collaborations
- R&D headquarters at JLABS @ Toronto in MaRS Discovery District, inside the Johnson & Johnson Innovation Centre
- Proprietary cannabinoid product lines addressing consumer retail, medical cannabis and Rx markets, including Pura H&W™ and RHO Phyto™
- Pharmaceutical pipeline of dermatology, neurology, oncology and pain management products
- World-class vertical integration, cultivation, extraction, purification, production, and manufacturing (global GMP Certifications)
- Low cost and sustainable cultivation, with 480,000 sq ft in Santa Marta, Colombia



Pura H&W: CBD Consumer Retail Products

Functional and evidence-based CBD derma-cosmetics addressing the emerging global CBD cosmetics segment. Utilizing a scientific approach, advanced products and supported by completed clinical studies.



PRODUCT EXPECTATIONS*

Table with columns for time period (Q4-2019, H1-2021) and regions (Colombia, USA, Canada, EU, Brazil + Ecuador) with descriptions of retail partnerships.

*Product launch expectations conditional upon regulatory approvals. **Expected to be marketed as Pura Earth in Canada. Pura Earth products in Colombia are being rebranded to Pura H&W.

Proprietary Clinical Development Platform

With ongoing clinical trials on its medical cannabis (RHO Phyto) and pharmaceutical pipeline products, Avicanna's commitment to researching the important role that cannabinoids play in an increasingly wider scope of products has been at the core of the Company's vision since its inception.

Timeline chart showing the progress of All Clinical Projects through Pre-Clinical, Protocol Development, Ethics Approval, Clinical Study, and Registration stages. Categories include Cosmetic Trials, Real-World Evidence (RHO Phyto), and Pharmaceutical Trials.

*Phase I studies not required for this product; Pending regulatory approval. ** Cosmetic product registration in Colombia and EU

H1-2021 goals: Launch RHO Phyto across retail channels in Canada; Commercialize Pura H&W in the UK and USA; Commercialize Pura Earth in Canada and Ecuador; Indication specific drug registration in Colombia; Commence export of RHO Phyto into LATAM and EU.

H2-2021 goals: Indication specific drug registrations in Brazil and Ecuador; Conclude RWET's on RHO Phyto; Commence Phase II trials on Epidermolysis Bullosa; Expand RHO Phyto and Pura H&W to other LATAM markets.

Recent News

- Dec 23rd, 2020 - Avicanna to Expand Access to Its Advanced and Evidence-Based RHO Phyto Medical Products Through Provincial Retailers Across Canada
Dec 17th, 2020 - Avicanna Expands Distribution Network in South America Through Commercial Partnerships in Ecuador and Commercial Export of Feminized Seeds to Uruguay
Dec 10th, 2020 - Avicanna Launches Medical Cannabis Program with its RHO Phyto Formulary Nationwide in Colombia
Dec 8th, 2020 - Avicanna Announces Closing of Public Offering of Units

Executive Management Team

- Aras Azadian, CEO, Director, and Co-Founder
Setu Purohit, President, Director, and Co-Founder
Dave Sohi, Chief Financial Officer
Dr. Amza Ali, Chief Medical Officer
Lucas Nosiglia, CAO and President of LATAM
Dr. Justin Grant, EVP Scientific Affairs
Ivana Maric, EVP Marketing

Investor Contact

ir@avicanna.com

Company Contact

Avicanna Inc. 480 University Ave, Suite 1502 Toronto, ON M5G 1V2 Canada P: (647) 243-5283 www.Avicanna.com

This document and the material contained herein are confidential and are not to be disclosed to the public. This is for information purposes only and may not be reproduced or distributed to any other person or published, in whole or part, for any purpose whatsoever.